TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Detection of Minimal Change Esophagitis Using Confocal Laser Endomicroscopy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Cases:~  * male or female patients aged between 21 and 65 years with typical clinical manifestations of gastroesophageal reflux but endoscopy-negative for esophageal mucosal breaks~ * by typical clinical manifestations of gastroesophageal reflux, we refer to the occurrence of heartburn and/or regurgitation more than twice a week, with a minimum duration of 8 consecutive weeks, and with symptoms severe enough to affect daily activities~* Controls:~  * healthy male or female aged between 21 and 65 years who are asymptomatic for GERD and other digestive diseases~Exclusion Criteria:~* Endoscopic confirmed erosive esophagitis~* Complications such as Barrett's esophagus, gastric and/or duodenal peptic ulcer, stenosis~* Esophageal, gastric or duodenal cancer or other malignancy~* History of esophagus, stomach, or duodenum surgery~* Conditions that preclude safe biopsies (coagulopathy, haemophilia, esophageal varices, and patients on warfarin and antiplatelets)~* Scleroderma, diabetes mellitus, autonomic or peripheral neuropathy, myopathy or any underlying disease or medication that might affect the lower esophageal sphincter pressure or increase the acid clearance time~* A history of bronchial asthma, or known allergy to fluorescein~* Pregnant or breast-feeding (for females)~* Below 21 or above 65 years of age~* Severe co-morbidities (e.g., such as end-stage renal failure, congestive cardiac failure, liver cirrhosis, severe arthritis requiring long term non-steroidal anti-inflammatory drug therapy)~* Unable or unwilling to give informed consent

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Case (subjects with NERD) (Type: None): The investigators cases are subjects with confirmed NERD and include male or female patients aged between 21 and 65 years, who present with typical clinical manifestations of gastroesophageal reflux and have no esophageal mucosal breaks upon conventional white-light endoscopy examination but show evidence of pathologic gastroesophageal reflux on 24-hr pH monitoring.
- Control (Type: None): Healthy individuals aged between 21 and 65 years who are asymptomatic for GERD and other digestive diseases

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study for Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects participating in this study must have completed treatment and all required evaluations in the previous MBP8298-01 study A Double Blind Placebo Controlled Multi-Centre Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis,~2. Subject must be able and willing to give meaningful, written informed consent prior to participation in the trial in accordance with regulatory requirements,~3. In the Investigator's opinion, subjects must be reliable, compliant and agree to cooperate with all trial evaluations.~Exclusion Criteria:~1. Use of any concomitant disease modifying therapy for Multiple Sclerosis e.g. ß-interferon, glatiramer acetate or mitoxantrone, cyclophosphamide, methotrexate, azathioprine, or any other immuno-modulating (e.g. IVIG) or immunosuppressive drugs including recombinant or non-recombinant cytokines.~2. Any medical, psychiatric or other condition that could result in a subject not being able to give fully informed consent, or to comply with the protocol requirements.~3. Any other condition that, in the Investigator's opinion, makes the subject unsuitable for participation in the study.~4. Females who are breast feeding, pregnant or not using a medically approved method of contraception regularly.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dirucotide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Smoking Relapse Prevention Among COPD Ex-smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Daily smokers~* Diagnosed with COPD (as per the Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] criteria, namely: a characteristic clinical picture of dyspnea, cough or sputum, with a history of exposure to risk factors, plus a post-bronchodilator forced expiratory volume in one second / forced vital capacity FEV1/FVC ratio of \<0.70)~* Have stable COPD (i.e. no exacerbation, hospital admission, or use of antibiotics or prednisone in the past six weeks)~* Can provide consent~* Reside in the Auckland region of New Zealand~* Eligible under New Zealand special authority to receive subsidised varenicline~* Prepared to make a quit attempt with varenicline~* Have access to a phone~Exclusion Criteria:~* A history of definite asthma and/or atopy~* Contraindications to varenicline~* Used varenicline in the past 12 months~* A history of serious psychiatric illness or significant cognitive impairment~* Major or uncontrolled co-morbidities (such as uncontrolled heart failure, infection or rapidly progressive condition)~* A life expectancy of \< 12 months~* Are currently using another cessation medication (including e-cigarettes)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Varenicline plus behavioural support (Type: ACTIVE_COMPARATOR): 12 weeks extended treatment with varenicline, plus relapse prevention-orientated behavioural support
- Placebo plus behavioural support (Type: PLACEBO_COMPARATOR): 12 weeks extended treatment with placebo, plus relapse prevention-orientated behavioural support

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti-anxiety Biotics for Breast Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Female breast cancer survivors or female relatives of a breast cancer survivor who:~1. are 50 years of age or older~2. have completed primary treatment~3. currently experience clinical anxiety symptoms determined by the 7 item Generalized Anxiety Disorder screener (GAD-7; eligibility requires a total score of 5 or higher on the 21 point scale)~4. agree not to change dietary supplements throughout the course of the study~5. are willing to comply with daily supplement regimen~6. are able to speak and read English.~Exclusion Criteria:~1. use of any of the following drugs within the last 4 weeks (unless indefinitely prescribed): systemic antibiotics, corticosteroids, immunosuppressive agents, or commercial probiotics~2. changes in treatment for anxiety symptoms (i.e. initiation of Cognitive Behavior Therapy (CBT) within the last four weeks~3. current use (within 12 weeks) of anxiolytic medications.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Synbiotic supplement group (Type: EXPERIMENTAL): Daily consumption of pills containing prebiotics and probiotics
- Placebo group (Type: PLACEBO_COMPARATOR): Daily consumption of pills containing maltodextrin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Topical Therapy for Treatment of Scalp Actinic Keratoses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age of at least 40 years.~* Presence of four to fifteen clinically typical, visible, and discrete actinic keratoses in 25 cm2 on the scalp.~* Ability and willingness of the patient to participate in the study (Informed consent is obtained)~Exclusion Criteria:~* Treatment area is within 5 cm of an incompletely healed wound or a suspected basal-cell or squamous-cell carcinoma~* Treatment area contains hypertrophic/hyperkeratotic lesions, cutaneous horns, or lesions that had not responded to repeated cryotherapy~* Recent (within a month) use of medications that could interfere with evaluation of the treatment area (e.g., topical medications, artificial tanners, immunosuppressive medications, immunomodulating agents, cytotoxic drugs, ultraviolet B phototherapy, other therapies for actinic keratoses, or oral retinoids)~* Premenopausal Women (to avoid any risk of pregnancy)~* History of hypercalcemia or clinical evidence of vitamin D toxicity (avoidance of calcipotriene toxicity).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Combination treatment arm (Type: EXPERIMENTAL): Combination of calcipotriene 0.005% foam (Sorilux) and Fluorouracil Cream, 5% USP (generic) applied for four consecutive nights for the treatment of scalp actinic keratoses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with proven SARS-CoV-2 infection by an accepted assay with symptoms consistent with COVID-19~* Ability to measure and quantify viral load by quantitative PCR~* Age 18 to 89~* Ability to swallow oral medications~* Patients must read, understand and sign IRB approved informed consent~Exclusion Criteria:~* Pregnancy or women who are breast feeding~* Two consecutive negative assays for SARS-CoV-2 infection~* Patients that lack decision-making capacity will not be approached to participate in this study~* Inability to tolerate oral medications~* Allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate~* QTc interval \> 470 mSEC~* History of ongoing ventricular cardiac dysrhythmias of grade 2 as described by NCI CTCAE 5.0 criteria~* History of serious ventricular arrhythmia (VT or VF \> 3 beats in a row)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Hydroxychloroquine Sulfate + Azithromycin (Type: EXPERIMENTAL): * Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days~* Azithromycin 500 mg taken by mouth on Day 1, followed by~* Azithromycin 250 mg taken by mouth once (1) time a day for four (4) days.
- Arm 2: Hydroxychloroquine Sulfate alone (Type: EXPERIMENTAL): • Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days
- Arm 3: Placebo (Type: NO_INTERVENTION): * Placebo pills Days 1-6.~* If you still have COVID-19 symptoms you will receive Hydroxychloroquine sulfate 200 mg by mouth three (3) times a day for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Crossover Study From Macitentan or Bosentan Over to Ambrisentan

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of a Connective Tissue Disease (CTD)~* Age range: 18-80 years old~* Previous Right Heart Catheterization (RHC) demonstrating PAH~* Forced vital capacity (FVC) greater than 50%~* Carbon Monoxide Diffusing Capacity (DLCO) greater than 50%~* World Health Organization (WHO) functional class II or III~* Able to perform a 6 minute walk test (6MWT)~* Stable dose of antihypertensive medications~* Non-pregnant females~* Have to be currently on stable dose of bosentan for at least 3 months~* Adequate acoustic images to allow for transthoracic echocardiography to be performed~Exclusion Criteria:~* Exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis)~* Severe systemic hypertension greater than 170/95~* Patients with a prior history of cardiovascular disease~* WHO functional class IV status~* Patients with severe other organ disease felt by investigators to impact on survival during the course of the study.~* FVC less than 50% of predicted~* DLCO less than 50% of predicted

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Switch to Letairis from Bosentan (Type: EXPERIMENTAL): Subjects will be switching treatments from Bosentan (Tracleer) to Ambrisentan (Letairis)
- Switch to Letairis from Macitentan (Type: EXPERIMENTAL): Subjects will be switching treatments from Macitentan (Opsumit) to Ambrisentan (Letairis)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Different Sports Supplements on Metabolism and Perceptual Responses During Distance Running

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be currently running ≥15 miles per week~* Have completed at least one run \>60 minutes over the past month~* Have completed one or more marathons within the past year~Exclusion Criteria:~* Overt cardiovascular disease or metabolic disorder~* Adverse symptoms (e.g., unusual shortness of breath, dizziness, chest pain) with exercise~* Allergies/intolerances to any of the ingredients in the beverages

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Carbohydrate Beverage (Type: EXPERIMENTAL): A glucose-fructose beverage mixture supplying 100 grams of carbohydrate per day for 5 days
- Placebo Beverage (Type: PLACEBO_COMPARATOR): An artificially-sweetened beverage containing aspartame

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* CCMC: Children ages 7-22 years (inclusive) with documented sickle cell disease~* UCHC: Adults 18 years (inclusive) and above with documented sickle cell disease~* Sudden onset of acute pain consistent with a vasoocclusive episode -Pain requiring hospitalization, placement on pain protocol, and patient- controlled opiates~* Pain score of greater than or equal to 5 out of 10 when ketamine infusion is started~* Cognitive ability to report pain on a 0 to 10 Numerical Rating Scale (NRS)~* At least one prior hospitalization for vasoocclusive pain at CCMC in the previous 24 months~* Parental consent and child assent~Exclusion Criteria:~* Children hospitalized for a primary diagnosis other than vasoocclusive episode~* Concurrent Acute Chest Syndrome (ACS)~* Hemoglobin \< 5 mg/dL~* Concurrent history of glaucoma or raised intracranial pressure~* Signs or symptoms consistent with stroke~* History of liver or renal dysfunction~* Pregnancy (females age 12 and above must have pregnancy test)~* Simultaneous participation in investigational drug study~* Primary language spoken other than English~* No hospitalizations to CCMC for vasoocclusive pain in the previous 24 months

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): This group will receive ketamine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Repair of Challenging Abdominal Wall Defects: Strattice(TM) TM in Abdominal Wall Repair (StAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults (18years of age or older) who is able to provide written informed consent for study participation~* has need of surgical intervention for repair of (potentially) contaminated abdominal wall defect of \>3cm and \<22cm in length, where the viscera have not been exposed for more than 15 days in case of open abdomen(skin and fascia open).~* Is willing and able to return for all scheduled \& required study visit.~Exclusion Criteria: at the time of randomization~* severe systemic sepsis~* frank pus in the wound, a fistula that will not be closed at the time of surgery or intra-abdominal abscess in surgical area,~* ongoing necrotizing pancreatitis,~* Is on chronic immunosuppressive therapy, or other medication that influences wound healing~* requires only short-term temporary closure,~* requires a synthetic, non-absorbable mesh to close the abdominal wall defect~* is unable to undergo general anesthesia,~* has other major organ system dysfunction or disorder that would jeopardize subject completing the 24 month study.~* Is unable to undergo an MRI scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Strattice(TM) TM repair (Type: ACTIVE_COMPARATOR): Strattice(TM) TM will be placed in the intraperitoneal or retrorectus position to support the repair of abdominal wall defect
- Standard of Care repair (Type: ACTIVE_COMPARATOR): Abdominal wall defect will be repaired using current standard of care techniques of either suture alone or suture with absorbable surgical mesh

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Modification of Hemostasis During Ventricular Assist Device Implantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years old~* Who gave his consent to the study~* With an end-stage heart-failure~* Under surgery for a ventricular assist device implantation~* Scheduled or in emergency~Exclusion Criteria:~* Preoperative anemia less than 7 g/dL~* Subject under the protection of justice~* Subject under guardianship or curatorship~* Pregnancy~* Breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed 104 weeks of study WA19977 with at least a JIA ACR30 clinical response to RoActemra/Actemra and no serious adverse event or adverse event~* Written informed consent obtained from patient if patient is 18 years of age and older, or if under the age of 18 years from parents or legal guardian~Exclusion Criteria:~* Patient did not benefit from RoActemra/Actemra therapy in study WA19977~* Treatment with any investigational drug since the last administration of study drug in the core study WA19977~* Patients developed any other autoimmune rheumatic disease other than the permitted JIA subsets~* Any significant medical or surgical condition that would jeopardize patient's safety~* Current serious uncontrolled concomitant disease or infection

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy